Report on an international patient traveling to access a newly available CAR-T cellular therapy for a solid tumor at a Chinese cancer center.
Key Takeaways
- 59-year-old patient from New Zealand with advanced gastroduodenal cancer
- After multidisciplinary evaluation and treatment planning at JICC, Josh successfully completed leukapheresis
- His CAR-T cells have now entered the manufacturing process, with reinfusion scheduled in the coming weeks